AstraZeneca (LSE:AZN) recently experienced a weekly price move of 2% amid announcements that could have supported its ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

AstraZeneca AZN reported positive top-line results from a late-stage study evaluating the safety, tolerability and efficacy ...

Astra said its experimental drug Baxdrostat reduced the blood pressure of patients who have a treatment-resistant form of ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary endpoints in the BaxHTN Phase III trial, effectively lowering blood pressure ...

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...